^
Association details:
| Biomarker: | BCR-ABL1 fusion |
|---|---|
| Cancer: | Acute Lymphocytic Leukemia |
| Drug: | Hansoh Xinfu (flumatinib) (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
4049 A Phase II Study of Flumatinib with Chemotherapy for Newly Diagnosed Ph/BCR-ABL1-Positive Acute Lymphoblastic Leukemia in Adults：Preliminary Results from RJ-ALL2020.2A Trial
Published date:
11/03/2022
Excerpt:
Pts who underwent HSCT had a relatively better outcome, with 1-year PFS rate significantly higher than non-HSCT group (95.7% vs. 52.2%, p=0.006) (Figure 1C), and 1-year OS rate tending to be higher (100% vs. 74.1%, p=0.145). Among 40 pts evaluable for ABL1 mutations, 14 pts were mutated...The combination of the second-generation TKI flumatinib and chemotherapy is quite effective and safe in Chinese adult pts with newly diagnosed Ph/BCR-ABL1+ ALL.
Secondary therapy:
Chemotherapy
DOI:
https://doi.org/10.1182/blood-2022-165259
